KRAS-Targeted Therapies in Advanced Solid Cancers: Drug the Undruggable?

PharmacogenomicsVol. 22, No. 10 EditorialKRAS-targeted therapies in advanced solid cancers: drug the undruggable? Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie E-mail Address: khalilₛaleh@live. comhttps: //orcid. org/0000-0002-2985-2202Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France, Manal KordahiDepartment of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon, Tony FeleflyDepartment of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon, Hampig Raphael KourieDepartment of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon & Nadine KhalifeDepartment of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, FrancePublished Online: 21 Jun 2021https: //doi. org/10. 2217/pgs-2021-0045AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adagrasibcolorectal cancerKRASG12C mutationsnon-small-cell lung cancerRASsotorasibReferences1. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell 170 (1), 17–33 (2017). Crossref, Medline, CAS, Google Scholar2. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19 (8), 533–552 (2020). Crossref, Medline, CAS, Google Scholar3. Network Cancer Genome Atlas Research. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (7511), 543–550 (2014). Crossref, Medline, Google Scholar4. Network Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (7407), 330–337 (2012). Crossref, Medline, Google Scholar5. Network Cancer Genome Atlas Research. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32 (2), 185–203. e13 (2017). Crossref, Medline, Google Scholar6. Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12C somatic mutations across race, sex, and cancer type. N. Engl. J. Med. 384 (2), 185–187 (2021). Crossref, Medline, Google Scholar7. Veluswamy R, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR. KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing. J. Mol. Diagn. 23 (5), 507–520 (2021). Crossref, Medline, CAS, Google Scholar8. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13 (10), 2890–2896 (2007). Crossref, Medline, CAS, Google Scholar9. Jones RP, Sutton PA, Evans JP et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116 (7), 923–929 (2017). Crossref, Medline, CAS, Google Scholar10. Canon J, Rex K, Saiki AY et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575 (7781), 217–223 (2019). Crossref, Medline, CAS, Google Scholar11. Hong DS, Fakih MG, Strickler JH et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383 (13), 1207–1217 (2020). Crossref, Medline, CAS, Google Scholar12. IASLC. Sotorasib shows early activity against KRAS G12C mutant NSCLC. https: //www. iaslc. org/iaslc-news/ilcn/sotorasib-shows-early-activity-against-kras-g12c-mutant-nsclcGoogle Scholar13. Hallin J, Engstrom LD, Hargis L et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10 (1), 54–71 (2020). Crossref, Medline, CAS, Google Scholar14. Jänne PA, Rybkin II, Spira AI et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small-cell lung cancer (NSCLC) harboring KRAS G12C mutation. Eur. J. Cancer 138, S1–S2 (2020). Crossref, Medline, Google Scholar15. Johnson ML, Ou SHI, Barve M et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur. J. Cancer 138, S2 (2020). Crossref, Google Scholar16. Amodio V, Yaeger R, Arcella P et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10 (8), 1129–1139 (2020). Crossref, Medline, CAS, Google Scholar17. Ryan MB, Fece de la Cruz F, Phat S et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer Res. 26 (7), 1633–1643 (2020). Crossref, Medline, CAS, Google Scholar18. Misale S, Fatherree JP, Cortez E et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25 (2), 796–807 (2019). Crossref, Medline, CAS, Google Scholar19. Tanaka N, Lin JJ, Li C et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. doi: 10. 1158/2159-8290. CD-21-0365 (2021) (Epub ahead of print). Crossref, Medline, Google Scholar20. Mark Awad. AACR Annual Meeting 2021 Online Proceedings and Itinerary Planner. Dana-Farber Cancer Institute, MA, USA. https: //www. abstractsonline. com/pp8/#!/9325/presentation/4751Google ScholarFiguresReferencesRelatedDetailsCited ByThe KRAS-G12C inhibitor: activity and resistance1 September 2021 | Cancer Gene Therapy, Vol. 29, No. 7Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges4 October 2021 | Molecular Cancer, Vol. 20, No. 1 Vol. 22, No. 10 Follow us on social media for the latest updates Metrics Downloaded 195 times History Received 13 April 2021 Accepted 7 June 2021 Published online 21 June 2021 Published in print July 2021 Information© 2021 Future Medicine LtdKeywordsadagrasibcolorectal cancerKRASG12C mutationsnon-small-cell lung cancerRASsotorasibFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. PDF download